Drug Trial Radar · NCT06617416
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
Last checked: Nov 20, 2026Latest source record: Mar 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
560
Planned (sponsor's estimate)
Start
Nov 12, 2024
Primary completion
Oct 28, 2026
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Sep 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study compares the efficacy and safety of AK104 versus Sugemalimab as consolidation therapy in patients with unresectable, locally advanced NSCLC who have not progressed following concurrent or sequential chemoradiotherapy.
Conditions
- NSCLC (Non-small Cell Lung Cancer)
Interventions
Cadonilimab (AK104)Drug
AK104 ivgtt Q3W
SugemalimabDrug
1200mg Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) assessed by INVTime frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital of Shandong First Medical University
Jinan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.